ArticleFrontiers in neurology2025
Identifying depression with mixed features: the potential value of eye-tracking features.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Early screening of mild cognitive impairment based on eye-tracking technology: a cross-sectional study.Aging clinical and experimental research · 2026Article
- Artificial Intelligence-Based Depression Detection.Sensors (Basel, Switzerland) · 2026Article
- A virtual reality-based multimodal framework for adolescent depression screening using machine learning.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the utility of eye-tracking features as a neurobiological marker for identifying depression with mixed features (DMF), a psychiatric disorder characterized by the presence of depressive symptoms alongside subsyndromal manic features, thereby complicating both diagnosis and therapeutic intervention. Methods: A total of 93 participants were included, comprising 41 patients with major depressive disorder (MDD), of whom 20 were classified as DMF, and 52 healthy controls (HC). Eye-tracking features were collected using an infrared-based device, and participants were evaluated using clinical scales including the Montgomery-Åsberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), and Brief Psychiatric Rating Scale (BPRS). Performance of extreme gradient boosting (XGBoost) model based on demographic and clinical characteristics was compared with that of the model created after adding ocular movement data. Results: Significant differences were observed in certain eye-tracking features between DMF, MDD, and HC, particularly in orienting saccades and overlapping saccades. Incorporating eye-tracking features into the XGBoost model enhanced the predictive accuracy for DMF, as evidenced by an increase in the area under the curve (AUC) from 0.571 to 0.679 ( Conclusion: Eye-tracking features, especially the velocity of overlapping saccades and free viewing task completion time, hold potential as non-invasive biomarkers for the identification of DMF. The integration of these parameters into the XGBoost machine learning model significantly improved the accuracy of DMF diagnosis, offering a promising approach for enhancing clinical decision-making in psychiatric settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.